SenzaGen AB

SenzaGen AB

Health CarePharmaceuticals and Biotechnology
  • Price (SEK)11.00
  • Today's Change-0.150 / -1.35%
  • Shares traded3.74k
  • 1 Year change+37.50%
  • Beta0.8782
Data delayed at least 15 minutes, as of May 30 2023 09:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.

  • Revenue in SEK (TTM)41.77m
  • Net income in SEK-24.91m
  • Incorporated2010
  • Employees16.00
  • Location
    SenzaGen ABMedicon VillageBuilding 401, Scheelevagen 2LUND 223 63SwedenSWE
  • Phone+46 462756200
  • Websitehttps://senzagen.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
Toxhub SrlDeal completed11 Nov 202211 Nov 2022Deal completed-14.40%306.00k
Data delayed at least 15 minutes, as of May 30 2023 09:59 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Moberg Pharma AB (publ)207.00k-16.30m209.28m----0.3854--1,011.03-1.88-1.880.023153.840.0004--0.0348---3.25---3.36--100.00---7,873.43------0.0091-----78.392.40------
Active Biotech AB publ0.00-58.40m212.17m11.00--6.15-----0.2475-0.24750.000.13020.00-------108.34-33.26-136.13-77.77-------600.78---144.750.1131-------17.21------
ExpreS2ion Biotech Holding AB6.66m-131.08m214.48m28.00--2.06--32.19-3.36-3.360.1722.110.0548--5.19222,066.70-107.81-58.88-120.43-69.62-208.6925.33-1,967.53-394.75----0.0547---55.21-8.89-170.02--13.21--
Arctic Bioscience AS33.34m-33.10m227.09m----0.7806--6.81-1.40-1.401.4111.790.10240.70723.24---10.17---11.20--33.98---99.28--4.03--0.00--59.29--20.09------
Abliva AB31.00k-79.33m228.69m6.00--1.53--7,377.06-0.1162-0.11620.000040.14110.0003--0.0015,166.67-72.67-73.09-81.76-85.88-----255,896.80-78,072.63---37.560.00---79.472.8030.96---26.59--
Mendus AB (publ)0.00-141.37m232.50m33.00--0.4812-----0.7128-0.71280.002.420.00----0.00-21.18-21.38-22.98-23.23-------28,264.99---27.860.1429-------4.03------
Kancera AB0.00-57.98m232.70m7.00--2.54-----1.01-,023.47---78.970.00-------14.88------
Lifecare AS21.54m-17.00m244.26m----4.54--11.34-0.148-0.1480.18780.46880.4332--30.31---34.20-41.60-39.09-47.04-----78.96-147.96----0.00--1,284.20109.30-10.08------
Opticept Technologies AB11.47m-106.25m263.04m----0.6942--22.94-5.26-5.260.513412.690.02730.59372.14---25.20-44.86-27.03-49.01-6.0642.23-922.44-863.201.45-11.150.0593--136.46122.77-112.89--35.79--
SenzaGen AB41.77m-24.91m268.32m16.00--3.01--6.42-1.03-1.031.733.710.32924.244.56---19.63-25.18-24.68-27.9565.4478.89-59.64-214.331.86--0.0133--170.85105.0320.53---29.85--
Initiator Pharma A/S0.00-50.60m283.32m----7.38-----1.00-
Biovica International AB3.88m-91.85m289.32m33.00--1.92--74.59-2.81-2.810.11693.820.0216-1.678.55155,160.00-51.17-30.85-55.61-33.47152.10332.81-2,367.83-1,470.098.35-543.410.0592---1.5426.47-51.97------
Intellego Technologies AB57.78m-9.96m316.24m----15.09--5.47-0.4567-0.45672.790.94780.57034.309.42---9.83---19.07--53.79---17.24--0.6917-3.080.5113--531.64---151.46------
AlzeCure Pharma AB0.00-53.14m317.89m12.00--6.24-----1.01-
Exact Therapeutics AS0.00-39.02m329.80m8.00--5.21-----1.34-1.340.002.17-----------28.38---32.26------------0.0252--------------
Corline Biomedical AB27.88m4.20m330.96m8.0078.803.4677.5611.870.19540.19541.304.450.2778--9.88--4.18-7.764.49-8.5899.92151.1415.07-76.39----0.00--233.47105.79133.65--12.38--
Data as of May 30 2023. Currency figures normalised to SenzaGen AB's reporting currency: Swedish Krona SEK

Institutional shareholders

0.79%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 31 Dec 2022190.50k0.79%
Data from 31 Mar 2023 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.